Leukemia

Experts on graft-vs-host disease offer clinical insights for clinicians treating patients with GVHD.

Experts discuss findings presented at ASH 2022 regarding chronic lymphocytic leukemia, and how they can be applied to clinical practice.

A panel of experts from Moffitt and Mayo discuss newly published data from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.

An esteemed panel of experts overviews new approaches being explored for treating graft-vs-host disease.

A detailed discussion on first-line treatment options for chronic GVHD and options for patients with steroid-refractory chronic GVHD.

Experts on graft-vs-host disease discuss patient monitoring and education, and a patient details his experience with GVHD.

A panel of GVHD experts give a comprehensive overview of the presentations of acute and chronic graft-vs-host disease.

Experts on graft-vs-host disease review GVHD and methods of prophylaxis preceding transplant.

EP0042 shows promising early clinical efficacy in patients with pretreated acute myeloid leukemia, according to investigators.

Further research is necessary to determine whether regular DNA sequence testing for residual disease variants in patients with acute myeloid leukemia can improve outcomes.

Adult patients with chronic lymphocytic leukemia in the European Union can now receive treatment with acalabrutinib tablets.

A qualitative, interview-based analysis identified 7 distinct roles played by hematologists relating to shared decision making for patients with advanced lymphoma or leukemia.

Data from the European phase 1 MB-105 trial indicate that the safety profile of annamycin in geriatric advance acute myeloid leukemia are consistent with previously reported findings.

An expert from the University of Texas MD Anderson Cancer Center says that ponatinib plus reduced-intensity chemotherapy may be a new standard of care for frontline Philadelphia chromosome–positive acute lymphoblastic leukemia.

Talha Badar, MBBS, MD, discussed the results of the phase 3 ASCEMBL trial, demonstrating the superiority of asciminib versus bosutinib in patients with chronic myeloid leukemia in chronic phase.

Dr Catherine Coombs explains the challenges of treating 17p deletions and Richter’s syndrome in patients with CLL and discusses the role of venetoclax in the treatment of these patients.

Seema Ali Bhat, MD, and Alexey Danilov, MD, PhD, discuss data updates on the use of fixed-duration venetoclax for the treatment of CLL.

CAR T-cell therapy brexucabtagene autoleucel appears to produce an overall survival benefit among patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Findings from a study indicate that measurable residual disease clearance is associated with favorable outcomes in acute myeloid leukemia following subsequent therapy before allogenic stem cell transplant.

Dr Seema Ali Bhat continues the conversation on non-covalent BTK inhibitors in CLL treatment with a look at nemtabrutinib and data from the BELLWAVE-001 study.

Catherine Coombs, MD, and Alexey Danilov, MD, PhD, discuss data on the investigational non-covalent BTK inhibitor pirtobrutinib for the treatment of CLL.

Investigators say that a phase 1/2 trial evaluating MGTA-117 in 2 hematologic malignancies has been paused following a serious adverse effect that may be related to the agent.

The panel explains the factors they consider when deciding on a BTK inhibitor for the treatment of patients with CLL.

Drs Susan O’Brien and Catherine Coombs describe the design and outcomes of the ELEVATE-RR and ALPINE trials that compare BTK inhibitors in CLL.

Eleanor Mayfield, ELS, discusses FLT3-ITD minimal residual disease in acute myeloid leukemia.